<PAPER><mode2 name='PMC2919700' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type='epub'>1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>2919700</article-id><article-id pub-id-type='publisher-id'>alzrt44</article-id><article-id pub-id-type='pmid'>20576109</article-id><article-id pub-id-type='doi'>10.1186/alzrt44</article-id><article-categories><subj-group subj-group-type='heading'><subject>Research</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease</s></article-title></title-group><contrib-group><contrib contrib-type='author' corresp='yes' id='A1'><name><surname>Stomrud</surname><given-names>Erik</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>erik.stomrud@med.lu.se</email></contrib><contrib contrib-type='author' id='A2'><name><surname>Björkqvist</surname><given-names>Maria</given-names></name><xref rid='I3' ref-type='aff'>3</xref><email>maria.bjorkqvist@med.lu.se</email></contrib><contrib contrib-type='author' id='A3'><name><surname>Janciauskiene</surname><given-names>Sabina</given-names></name><xref rid='I4' ref-type='aff'>4</xref><email>sabina.janciauskiene@med.lu.se</email></contrib><contrib contrib-type='author' id='A4'><name><surname>Minthon</surname><given-names>Lennart</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>lennart.minthon@skane.se</email></contrib><contrib contrib-type='author' corresp='yes' id='A5'><name><surname>Hansson</surname><given-names>Oskar</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>oskar.hansson@med.lu.se</email></contrib></contrib-group><aff id='I1'><label>1</label>Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University; SUS, 205 02 Malmö, Sweden</aff><aff id='I2'><label>2</label>Neuropsychiatric Clinic, Skåne University Hospital; 205 02 Malmö, Sweden</aff><aff id='I3'><label>3</label>Neuronal Survival Unit, Department of Experimental Medical Science, Lund University; Wallenberg Neuroscience Center, BMC A10, Sölvegatan 17, Lund, Sweden</aff><aff id='I4'><label>4</label>Wallenberg Laboratory, Department of Clinical Sciences Malmö, Lund University; SUS, 205 02 Malmö, Sweden</aff><pub-date pub-type='collection'><year>2010</year></pub-date><pub-date pub-type='epub'><day>24</day><month>6</month><year>2010</year></pub-date><volume>2</volume><issue>3</issue><fpage>20</fpage><lpage>20</lpage><history><date date-type='received'><day>5</day><month>2</month><year>2010</year></date><date date-type='accepted'><day>24</day><month>6</month><year>2010</year></date></history><permissions><copyright-statement>Copyright ©2010 Stomrud et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>Stomrud et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type='open-access' xlink:href='http://creativecommons.org/licenses/by/2.0'><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by/2.0'>http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href='http://alzres.com/content/2/3/20'></self-uri><abstract><sec><title>Introduction</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Matrix metalloproteinases (MMP) are believed to be involved in the pathologic processes behind Alzheimer's disease (AD).</s><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> In this study, we aimed to examine the cerebrospinal fluid (CSF) levels of MMPs and tissue inhibitors of metalloproteinase-1 (TIMP-1) in individuals with AD dementia and cognitively healthy elderly individuals, and to investigate their relationship with established CSF biomarkers for Alzheimer's disease.</s></p></sec><sec><title>Methods</title><p><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>CSF was collected from 38 individuals with AD dementia and 34 cognitively healthy elderly individuals.</s><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The CSF was analyzed for MMP-1, MMP-3, MMP-9, TIMP-1, β-amyloid<sub>1-42 </sub>(Aβ42), total tau protein (T-tau) and phosphorylated tau protein (P-tau).</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> MMP/TIMP-1 ratios were calculated. <italic>APOE </italic>genotype was determined for the participants.</s></p></sec><sec><title>Results</title><p><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>AD patients had higher MMP-9/TIMP-1 ratios and lower TIMP-1 levels compared to cognitively healthy individuals.</s><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In AD patients, the MMP-9/TIMP-1 ratio correlated with CSF T-tau, a marker of neurodegeneration.</s><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Interestingly, the cognitively healthy individuals with risk markers for future AD, i.e. AD-supportive CSF biomarker levels of T-tau, P-tau and Aβ42 or the presence of the <italic>APOE </italic>ε4 allele, had higher CSF MMP-3 and MMP-9 levels and higher CSF MMP-3/TIMP-1 ratios compared to the healthy individuals without risk markers.</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The CSF levels of MMP-3 and -9 in the control group also correlated with the CSF T-tau and P-tau levels.</s></p></sec><sec><title>Conclusions</title><p><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>This study indicates that MMP-3 and MMP-9 might be involved in early pathogenesis of AD and that MMPs could be associated with neuronal degeneration and formation of neurofibrillary tangles even prior to development of overt cognitive dysfunction.</s></p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Most cases of dementia are caused by Alzheimer's disease (AD), which is characterized by progressive accumulation of senile plaques, containing β-amyloid (Aβ), and neurofibrillary tangles, containing hyperphosphorylated tau [<xref rid='B1' ref-type='bibr'>1</xref>].</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This process probably starts many years before the typical clinical symptoms of AD appear.</s><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> However, the underlying pathologic mechanisms in AD are still to a large extent unknown and the target of extensive research.</s><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> There is increasing evidence indicating that matrix metalloproteinases (MMPs) may play an important but complex role in the pathology behind neurodegenerative disorders [<xref rid='B2' ref-type='bibr'>2</xref>-<xref rid='B4' ref-type='bibr'>4</xref>].</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> MMPs are zinc- and calcium-dependent endopeptidases, several of which are produced by neurons and glial cells.</s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> MMPs can be further divided into gelatinases (such as MMP-9), stromelysins (such as MMP-3), collagenases (such as MMP-1) and membrane-type MMPs (MT-MMP) [<xref rid='B2' ref-type='bibr'>2</xref>,<xref rid='B3' ref-type='bibr'>3</xref>].</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Their activity is determined through the induction of transcription by inflammatory mediators, through post-translational modification by free radicals or cytokines and through inhibitory proteins such as tissue inhibitors of metalloproteinases (TIMPs) [<xref rid='B3' ref-type='bibr'>3</xref>].</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The different TIMPs often have inhibitory effects on most MMPs.</s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, they usually have a predisposition to one or a few MMPs, for example the inhibitory effect of TIMP-1 is primarily directed towards MMP-9 [<xref rid='B2' ref-type='bibr'>2</xref>].</s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The tasks and effects of MMPs and TIMPs are complex, and the same MMP can have directly opposite effects on the brain depending on the situation, location, and time point in which it is being expressed.</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Their beneficial effects include neurogenesis, angiogenesis, myelinogenesis, axonal growth, and apoptosis inhibition, whereas examples of detrimental effects are apoptosis induction, blood brain barrier disruption and demyelination [<xref rid='B2' ref-type='bibr'>2</xref>,<xref rid='B3' ref-type='bibr'>3</xref>,<xref rid='B5' ref-type='bibr'>5</xref>].</s></p><p><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In AD, the expressions of MMP-3 and MMP-9 are elevated in the brain and are located around neurofibrillary tangles and amyloid plaques [<xref rid='B6' ref-type='bibr'>6</xref>-<xref rid='B8' ref-type='bibr'>8</xref>].</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The activity of MMPs might be associated with the metabolism of Aβ, because Aβ has been found to induce the expression of MMPs by both astrocytes and neurons [<xref rid='B9' ref-type='bibr'>9</xref>-<xref rid='B12' ref-type='bibr'>12</xref>].</s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Moreover, MMP-3 and MMP-9 can cleave and degrade Aβ fibrils [<xref rid='B8' ref-type='bibr'>8</xref>,<xref rid='B13' ref-type='bibr'>13</xref>].</s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Recently, it has been suggested that MMP-9 expression in the hippocampus is involved in Aβ-induced cognitive dysfunction [<xref rid='B10' ref-type='bibr'>10</xref>].</s><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> These findings together point to the need to increase our understanding of the role of MMPs in AD and their relation to other AD-related markers <italic>in vivo</italic>.</s></p><p><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Investigation of markers in cerebrospinal fluid (CSF) is a valuable method to study pathologic processes in the brain.</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> So far, the best validated CSF biomarkers for AD are low Aβ42 levels, high total tau protein (T-tau) levels and high levels of phosphorylated tau protein (P-tau).</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These biomarkers may also predict future AD dementia with acceptable accuracy in individuals with mild cognitive impairment (MCI) and they appear to be altered already in preclinical stages [<xref rid='B14' ref-type='bibr'>14</xref>-<xref rid='B20' ref-type='bibr'>20</xref>].</s><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Apart from these biomarkers, the presence of the apolipoprotein E (<italic>APOE</italic>) ε4 allele is another well-established risk factor for the development of AD dementia [<xref rid='B1' ref-type='bibr'>1</xref>].</s></p><p><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>The aim of this study was to investigate MMP-1, MMP-3, MMP-9 and TIMP-1 in the CSF of AD patients and healthy elderly controls, and their relation with the established CSF biomarkers Aβ42, T-tau and P-tau as well as the <italic>APOE </italic>genotype.</s></p></sec><sec sec-type='materials|methods'><title>Materials and methods</title><sec><title>Study population</title><p><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>The study population consisted of individuals with AD and healthy elderly individuals, who were all recruited at the Department of Neuropsychiatry at Malmö, Skåne University Hospital, Sweden.</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> All individuals with AD were patients who had been referred to the clinic due to cognitive decline and had undergone a clinical, routine investigation.</s><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Patients with AD fulfiling the <italic>Diagnostic and Statistical Manual of Mental Disorders </italic>(<italic>DSM</italic>)-IIIR criteria for dementia [<xref rid='B21' ref-type='bibr'>21</xref>] and the criteria for probable AD defined by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) [<xref rid='B22' ref-type='bibr'>22</xref>] were eligible for the study.</s></p><p><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>The healthy elderly individuals were collected from a clinical control group with four years of cognitive follow-up and were summoned for an additional cognitive assessment and subsequent CSF collection.</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> There is no clear, universal definition of the clinical characteristics of a cognitively healthy elderly individual.</s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In the present study the cognitively healthy individuals were not allowed to fulfill criteria for dementia [<xref rid='B21' ref-type='bibr'>21</xref>] or mild cognitive impairment [<xref rid='B23' ref-type='bibr'>23</xref>] after extensive clinical and cognitive assessments.</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In order to additionally decrease the presence of possible early-stage cognitive impairment in the group, a mini mental state examination (MMSE) score of 27 points or more was required.</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This score is supported by several large-scale, community-based, normative studies that have reported mean MMSE values of 25 to 28 for individuals between 60 and 85 years of age, depending on age and educational level [<xref rid='B24' ref-type='bibr'>24</xref>-<xref rid='B26' ref-type='bibr'>26</xref>].</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> As these studies might have included some individuals with minor impairments in cognitive functions, the MMSE cut-off score in the present study was set slightly higher than the previously reported community-based mean values.</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In the present study the cognitive assessment also included the Alzheimer's Disease Assessment Scale (ADAS-cog 85 points), clock test, cube copying test and A Quick Test of cognitive speed (AQT).</s><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> These results were taken into consideration in the decision whether dementia or MCI diagnosis criteria were fulfilled at the time of inclusion.</s></p><p><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The study was approved by the Regional Ethics Committee at Lund University.</s><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> All participants gave their consent to participate in the study.</s></p></sec><sec><title>Study investigations</title><p><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>All participants in the study had their <italic>APOE </italic>genotype determined through blood testing.</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> CSF collection was performed with the patient in a sitting position.</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After disposal of the first 1 ml of CSF, the next 10 ml were obtained from the L3/L4 or L4/L5 interspaces and collected in polypropylene tubes.</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The samples were centrifuged at 2,000 g at 4°C for 10 minutes to eliminate cells and other insoluble material, and were then immediately frozen and stored at -80°C pending biochemical analyses, without being thawed or refrozen.</s><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Cell count was performed on the CSF samples and no sample contained more that 500 erythrocytes/μl.</s></p><p><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>The CSF samples were analyzed for T-tau, tau protein phosphorylated at threonine 181 (P-tau) and Aβ42.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In the AD patients, CSF T-tau concentration was determined using a sandwich ELISA (Innotest<sup>® </sup>hTAU-Ag, Innogenetics, Ghent, Belgium) specifically constructed to measure all tau isoforms irrespective of phosphorylation status, as previously described [<xref rid='B27' ref-type='bibr'>27</xref>].</s><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> CSF P-tau levels were determined using sandwich ELISA (Innotest<sup>® </sup>PHOSPHO-TAU<sub>(181P)</sub>, Innogenetics, Ghent, Belgium).</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> CSF Aβ<sub>1-42 </sub>levels were determined using a sandwich ELISA (Innotest<sup>® </sup>β-amyloid (1-42), Innogenetics, Gent, Belgium) specifically constructed to measure Aβ containing both the 1<sup>st </sup>and 42<sup>nd </sup>amino acid, as previously described [<xref rid='B28' ref-type='bibr'>28</xref>].</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In the healthy elderly individuals analysis was performed with xMAP technology using the INNO-BIA AlzBio3 kit (Innogenetics, Ghent, Belgium) and the same batch of reagents [<xref rid='B29' ref-type='bibr'>29</xref>].</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Results from the Luminex xMAP system were converted to ELISA levels based on previously published conversion factors [<xref rid='B29' ref-type='bibr'>29</xref>].</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The results are presented in ng/l.</s></p><p><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The CSF MMP-1, MMP-3, MMP-9 and TIMP-1 levels were measured using commercially available immunoassays according to the instructions provided by the manufacturers 'Meso Scale Discovery' (Gaithersburg, MD, USA) and 'R&amp;D System' (Minneapolis, MN, USA), respectively.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> For the MMP assays a 12-point standard curve was used.</s><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The detection limit of the assay was 0.008 ng/ml of human recombinant MMP-1, 0.04 ng/ml of human recombinant MMP-3, 0.24 ng/ml of human recombinant MMP-9, and 0.031 ng/ml of human recombinant TIMP-1 with an inter-assay variation of less than 10%.</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The results are presented in ng/ml.</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The ratios of MMP-1/TIMP-1, MMP-3/TIMP-1 and MMP-9/TIMP-1 were additionally calculated.</s></p><p><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>For subgroup analyses, the healthy elderly individuals were divided according to deviant CSF biomarker levels and according to presence of the <italic>APOE </italic>ε4 allele, which are established risk markers for future dementia.</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Cut-off levels to define deviant CSF biomarker levels were determined at a CSF Aβ42/P-tau ratio of less than 6.5 combined with CSF T-tau levels of more than 350 ng/l.</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These cut-off levels were chosen because this combination has predicted future AD with a sensitivity of 95% and a specificity of 87% in a large MCI study population [<xref rid='B15' ref-type='bibr'>15</xref>].</s></p></sec><sec><title>Statistics</title><p><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Statistical analysis was performed using the PASW software (former SPSS software, version 17.0.1 for Windows, SPSS Inc., Chicago, IL, USA).</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Non-parametric tests were used because normal distribution could not be assumed in the groups.</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Spearman rank correlation coefficient (r<sub>s</sub>) was used to test the degree of correlation between CSF biomarkers, MMP and TIMP-1 levels as well as the influence of age.</s><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Mann-Whitney U test was used when one of the variables was dichotomized (group comparisons, presence of deviant CSF biomarker levels, <italic>APOE </italic>ε4 allele carrier and gender).</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Fisher's Exact Test was used if both variables were dichotomized (group comparisons of <italic>APOE </italic>ε4 allele carrier and gender).</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The level of significance was set to <italic>P </italic>&lt; 0.05.</s></p></sec></sec><sec><title>Results</title><sec><title>Participant characteristics</title><p><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The characteristics for the AD group and the group of healthy elderly individuals are presented in Table <xref rid='T1' ref-type='table'>1</xref>.</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The 38 AD patients had significantly higher CSF T-tau and CSF P-tau levels, lower CSF Aβ42 levels, lower MMSE scores and higher presence of the <italic>APOE </italic>ε4 allele compared with the 34 healthy elderly individuals.</s><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> No difference in age or gender was observed between the groups.</s></p><table-wrap id='T1' position='float'><label>Table 1</label><caption><p>Characteristics for the AD group and the group of healthy elderly individuals</p></caption><table rules='groups' frame='hsides'><thead><tr><th></th><th align='center'>AD</th><th align='center'>HC</th><th align='center'>Group difference</th></tr></thead><tbody><tr><td align='left'><bold>Demographics</bold></td><td></td><td></td><td></td></tr><tr><td align='left'> Number</td><td align='center'>38</td><td align='center'>34</td><td></td></tr><tr><td align='left'> Age</td><td align='center'>76 ± 7</td><td align='center'>77 ± 8</td><td align='center'>ns</td></tr><tr><td align='left'> Gender (F/M)</td><td align='center'>23/15</td><td align='center'>24/10</td><td align='center'>ns</td></tr><tr><td align='left'> MMSE</td><td align='center'>19 ± 5</td><td align='center'>29 ± 1</td><td align='center'><italic>P </italic>&lt; 10<sup>-12</sup></td></tr><tr><td align='left'> <italic>APOE </italic>ε4 heterozygote (homozygote)</td><td align='center'>63% (13%)</td><td align='center'>24% (3%)</td><td align='center'><italic>P </italic>&lt; 10<sup>-4</sup></td></tr><tr><td align='left'><bold>CSF**</bold></td><td></td><td></td><td></td></tr><tr><td align='left'> Aβ42</td><td align='center'>307 ± 91</td><td align='center'>647 ± 166</td><td align='center'><italic>P </italic>&lt; 10<sup>-11</sup></td></tr><tr><td align='left'> T-tau</td><td align='center'>938 ± 542</td><td align='center'>399 ± 194</td><td align='center'><italic>P </italic>&lt; 10<sup>-8</sup></td></tr><tr><td align='left'> P-tau</td><td align='center'>106 ± 55*</td><td align='center'>64 ± 28</td><td align='center'><italic>P </italic>&lt; 10<sup>-4</sup></td></tr><tr><td align='left'> MMP-1</td><td align='center'>0.024 ± 0.016</td><td align='center'>0.021 ± 0.01</td><td align='center'>ns</td></tr><tr><td align='left'> MMP-3</td><td align='center'>0.716 ± 0.35</td><td align='center'>0.700 ± 0.36</td><td align='center'>ns</td></tr><tr><td align='left'> MMP-9</td><td align='center'>0.902 ± 0.39</td><td align='center'>0.859 ± 0.35</td><td align='center'>ns</td></tr><tr><td align='left'> TIMP-1</td><td align='center'>0.035 ± 11.7</td><td align='center'>0.041 ± 13.0</td><td align='center'><italic>P </italic>&lt; 0.05</td></tr><tr><td align='left'> MMP-1/TIMP-1</td><td align='center'>0.697 ± 0.35</td><td align='center'>0.564 ± 0.25</td><td align='center'>ns</td></tr><tr><td align='left'> MMP-3/TIMP-1</td><td align='center'>21.1 ± 9.7</td><td align='center'>18.1 ± 9.8</td><td align='center'>ns</td></tr><tr><td align='left'> MMP-9/TIMP-1</td><td align='center'>26.9 ± 11.9</td><td align='center'>22.7 ± 11.8</td><td align='center'><italic>P </italic>&lt; 0.05</td></tr></tbody></table><table-wrap-foot><p>Aβ42, β-amyloid<sub>1-42</sub>; AD, Alzheimer's disease; APOE, apolipoprotein E; CSF, cerebrospinal fluid; F, female; HC, healthy controls; M, male; MMP, matrix metalloproteinase; MMSE, mini mental state examination; TIMP, tissue inhibitor of metalloproteinase.</p><p>* n = 28. ** Levels are in ng/l for Aβ42, T-tau and P-tau and in ng/ml for the MMPs and TIMP-1.</p></table-wrap-foot></table-wrap></sec><sec><title>CSF MMPs and TIMP-1 levels in the AD patients</title><p><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The CSF MMP-9/TIMP-1 ratios were significantly higher and the CSF TIMP-1 levels were significantly lower in the AD patients compared with the healthy elderly individuals (<italic>P </italic>&lt; 0.05; Table <xref rid='T1' ref-type='table'>1</xref>).</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Moreover, increased CSF T-tau levels correlated with high CSF MMP-9/TIMP-1 ratios (r<sub>s </sub>= 0.448, <italic>P </italic>&lt; 0.01) and MMP-3/TIMP-1 ratios (r<sub>s </sub>= 0.351, <italic>P </italic>&lt; 0.05) in the AD patients (Figures <xref rid='F1' ref-type='fig'>1</xref> and <xref rid='F2' ref-type='fig'>2</xref>). <italic>APOE </italic>genotype, age and gender did not correlate with the CSF MMPs and TIMP-1 levels or with the CSF MMP/TIMP-1 ratio.</s></p><fig id='F1' position='float'><label>Figure 1</label><caption><p><bold>Scatter plot of CSF MMP-9/TIMP-1 ratio and CSF T-tau levels in patients with Alzheimer's disease</bold>. CSF T-tau levels are presented in ng/l. CSF, cerebrospinal fluid; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase.</p></caption><graphic xlink:href='alzrt44-1'></graphic></fig><fig id='F2' position='float'><label>Figure 2</label><caption><p><bold>Scatter plot of CSF MMP-3/TIMP-1 ratio and CSF T-tau levels in patients with Alzheimer's disease</bold>. CSF T-tau levels are presented in ng/l. CSF, cerebrospinal fluid; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase.</p></caption><graphic xlink:href='alzrt44-2'></graphic></fig></sec><sec><title>CSF MMPs and TIMP-1 levels in the healthy elderly individuals</title><p><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>In the group of healthy elderly individuals, both higher levels of CSF MMP-9 and MMP-3 correlated with higher CSF T-tau levels (r<sub>s </sub>= 0.494, <italic>P </italic>&lt; 0.01 and r<sub>s </sub>= 0.557, <italic>P </italic>&lt; 0.001) and P-tau levels (r<sub>s </sub>= 0.435, <italic>P </italic>&lt; 0.05 and r<sub>s </sub>= 0.554, <italic>P </italic>&lt; 0.001; Figures <xref rid='F3' ref-type='fig'>3</xref> and <xref rid='F4' ref-type='fig'>4</xref>).</s><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> As seen in the AD participants, higher CSF MMP-3/TIMP-1 ratio correlated with higher CSF T-tau levels (r<sub>s </sub>= 0.352, <italic>P </italic>&lt; 0.05) but in healthy elderly individuals the ratio also correlated with higher CSF P-tau levels (r<sub>s </sub>= 0.376, <italic>P </italic>&lt; 0.05).</s></p><fig id='F3' position='float'><label>Figure 3</label><caption><p><bold>Scatter plot of CSF MMP-9 levels and CSF T-tau levels in the cognitively healthy elderly individuals</bold>. CSF MMP-9 levels are presented in ng/ml and CSF T-tau levels are presented in ng/l. CSF, cerebrospinal fluid; MMP, matrix metalloproteinase.</p></caption><graphic xlink:href='alzrt44-3'></graphic></fig><fig id='F4' position='float'><label>Figure 4</label><caption><p><bold>Scatter plot of CSF MMP-9 levels and CSF P-tau levels in the cognitively healthy elderly individuals</bold>. CSF MMP-9 levels are presented in ng/ml and CSF P-tau levels are presented in ng/l. CSF, cerebrospinal fluid; MMP, matrix metalloproteinase.</p></caption><graphic xlink:href='alzrt44-4'></graphic></fig><p><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The seven healthy elderly individuals with an AD-supportive CSF biomarker pattern (CSF Aβ42/P-tau ratio &lt;6.5 combined with CSF T-tau &gt;350 ng/l [<xref rid='B15' ref-type='bibr'>15</xref>]) had significantly higher levels of CSF MMP-9 (z = -2.37, <italic>P </italic>&lt; 0.05; Figure <xref rid='F5' ref-type='fig'>5</xref>) compared with the other 27 healthy elderly individuals.</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In addition, the nine <italic>APOE </italic>ε4 allele carriers had higher levels of CSF MMP-9 (z = -2.13, <italic>P </italic>&lt; 0.05; Figure <xref rid='F6' ref-type='fig'>6</xref>) and CSF MMP-3 (z = -2.23, <italic>P </italic>&lt; 0.05) compared with the 25 non-carriers.</s></p><fig id='F5' position='float'><label>Figure 5</label><caption><p><bold>Error plot of difference in CSF MMP-9 levels between the cognitively healthy elderly individuals with AD-indicative CSF biomarker levels (n = 7) compared with those with unaffected CSF biomarker levels (n = 27)</bold>. CSF MMP-9 levels are presented in ng/ml. AD, Alzheimer's disease; CSF, cerebrospinal fluid; MMP, matrix metalloproteinase.</p></caption><graphic xlink:href='alzrt44-5'></graphic></fig><fig id='F6' position='float'><label>Figure 6</label><caption><p><bold>Error plot of difference in MMP-9 levels between cognitively healthy elderly individuals with at least one <italic>APOE </italic>ε4 allele (n = 9) compared with those without the allele (n = 25)</bold>. CSF MMP-9 levels are presented in ng/ml. CSF, cerebrospinal fluid; MMP, matrix metalloproteinase.</p></caption><graphic xlink:href='alzrt44-6'></graphic></fig></sec></sec><sec><title>Discussion</title><p><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>In the present study we show that AD patients have a higher MMP-9/TIMP-1 ratio and a lower TIMP-1 level in CSF compared with cognitively healthy elderly individuals and that the MMP-9/TIMP-1 ratio in AD patients correlates with CSF T-tau, a marker of neuronal degeneration.</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In the group of healthy elderly individuals we observed that the individuals with risk markers for possible future AD, that is AD-supportive CSF biomarkers (tau and Aβ42) or presence of the <italic>APOE </italic>ε4 allele, have higher CSF MMP-3 and MMP-9 levels and a higher CSF MMP-3/TIMP-1 ratio compared with the individuals without risk markers.</s><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In addition, the CSF MMP-3 and MMP-9 levels correlate with the CSF T-tau and P-tau levels in the elderly controls.</s></p><p><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The findings of this study are in alignment with the elevated expression of MMP-3 and MMP-9 that have been observed in brain tissue of patients with established AD [<xref rid='B7' ref-type='bibr'>7</xref>,<xref rid='B8' ref-type='bibr'>8</xref>].</s><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In particular, MMP-9 has been observed to have elevated expression in the hippocampus, around senile plaques and neurofibrillary tangles and in vessel walls [<xref rid='B6' ref-type='bibr'>6</xref>,<xref rid='B8' ref-type='bibr'>8</xref>], whereas MMP-3 is expressed primarily around plaques in the parietal lobes [<xref rid='B7' ref-type='bibr'>7</xref>].</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Hence, the expression of these MMPs is located in the brain regions and adjacent to histologic features that are closely related to AD.</s><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, not all types of MMPs seem to be associated with AD pathogeneses.</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In the present study, MMP-1 (a collagenase) does not correlate with AD diagnosis or risk factors for future development of AD, a finding that is supported by a previous study that investigated the levels of different MMPs in plasma of AD patients [<xref rid='B30' ref-type='bibr'>30</xref>].</s></p><p><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>The increased levels of several MMPs in the CSF of individuals with increased risk for AD, as observed in the current study, could be explained by several plausible mechanisms associated with AD pathology.</s><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In general, the CSF levels of MMPs are influenced by the production of MMPs by neurons and glial cells, the release of MMPs by inflammatory cells and extravasation of MMPs from peripheral blood.</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> All of these mechanisms could be influenced by AD pathology.</s><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> For example, increased levels of plasma MMP-9 have been observed in AD patients [<xref rid='B30' ref-type='bibr'>30</xref>,<xref rid='B31' ref-type='bibr'>31</xref>].</s><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Both <italic>in vitro </italic>and <italic>in vivo </italic>studies have further suggested that the production of MMP-3 and MMP-9 are induced by AD-related proteins such as Aβ<sub>1-40 </sub>and Aβ<sub>1-42 </sub>[<xref rid='B9' ref-type='bibr'>9</xref>-<xref rid='B12' ref-type='bibr'>12</xref>].</s><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Finally, pro-inflammatory molecules, which exist in and contribute to the AD neurodegenerative process, are inducers of MMP-3 and MMP-9 expression both locally in the brain and in inflammatory cells recruited from the peripheral circulation [<xref rid='B2' ref-type='bibr'>2</xref>,<xref rid='B12' ref-type='bibr'>12</xref>,<xref rid='B32' ref-type='bibr'>32</xref>].</s></p><p><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>In the current study, CSF TIMP-1 levels were decreased and the MMP-9/TIMP-1 ratio was higher in AD patients when compared with healthy individuals.</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> This could suggest the presence of an imbalance between MMP-9 and TIMP-1 in AD patients, which leads to a predominant MMP-9 activity in the brain.</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> This idea is further supported by the association between high levels of CSF tau and high MMP-9/TIMP-1 ratios in the AD group.</s></p><p><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>A number of actions of MMPs and TIMPs, apart from the inflammatory response, have been closely linked to AD pathology.</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> For example, MMP-9 has been shown to be able to cleave and degrade Aβ40 and aggregated Aβ42 fibrils both <italic>in vitro </italic>and <italic>in vivo </italic>[<xref rid='B4' ref-type='bibr'>4</xref>,<xref rid='B8' ref-type='bibr'>8</xref>,<xref rid='B13' ref-type='bibr'>13</xref>].</s><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In light of these possible AD protecting effects of MMP-9, it has been suggested that the increased MMP-9 levels observed in AD might be of the inactive form [<xref rid='B2' ref-type='bibr'>2</xref>,<xref rid='B8' ref-type='bibr'>8</xref>,<xref rid='B12' ref-type='bibr'>12</xref>].</s><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This could explain why Aβ still accumulates into plaques despite the increased levels of certain MMPs.</s><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> It can further be noted that a specific MMP or TIMP has diverse effects on brain tissue depending on the situation, location and point in time of its expression and release [<xref rid='B2' ref-type='bibr'>2</xref>,<xref rid='B3' ref-type='bibr'>3</xref>].</s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> An alternative interpretation of the increased MMP levels in AD could be that the detrimental activity of MMPs, which leads to brain damage, exceeds its beneficial brain protective activity.</s><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Interestingly, Mizoguchi and colleagues [<xref rid='B10' ref-type='bibr'>10</xref>] have recently shown that Aβ-induced neurotoxicity <italic>in vitro </italic>as well as cognitive impairment <italic>in vivo </italic>is significantly alleviated by treatment with MMP inhibitors and significantly reduced in MMP-9 homozygous knockout mice, indicating that MMP-9 expression in the hippocampus might be involved in Aβ-induced cognitive dysfunction.</s><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Moreover, another study has shown increased activity of MMP-9 after stimulation with neurotoxic kainate in organotypic hippocampal cultures and reduced neuronal cell death after inhibition of MMP-9 [<xref rid='B33' ref-type='bibr'>33</xref>].</s><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Furthermore, in the same study, authors have shown that MMP-9 induces neuron death <italic>in vitro</italic>.</s><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Together these results indicate that MMP-9 might be involved in both Aβ-induced neuronal dysfunction as well as in excitotoxic cell death in the hippocampus.</s></p><p><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The progressive neurodegeneration in AD precedes the decline in cognitive function and dementia diagnosis by decades [<xref rid='B1' ref-type='bibr'>1</xref>].</s><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The CSF biomarkers tau and Aβ are today well validated markers for AD pathology and they are associated with development of AD dementia in individuals with mild cognitive impairment [<xref rid='B15' ref-type='bibr'>15</xref>-<xref rid='B17' ref-type='bibr'>17</xref>].</s><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Increasing evidence suggests that these CSF biomarkers indicate the presence of AD pathology also prior to the cognitive impairment, that is in cognitively unaffected elderly individuals [<xref rid='B18' ref-type='bibr'>18</xref>-<xref rid='B20' ref-type='bibr'>20</xref>,<xref rid='B34' ref-type='bibr'>34</xref>,<xref rid='B35' ref-type='bibr'>35</xref>].</s><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In the present study certain MMPs and TIMP-1 levels were related to these CSF biomarkers.</s><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Interestingly, MMP-3 and MMP-9 were elevated in healthy elderly individuals with CSF biomarker levels implying an increased risk of future development of AD.</s><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In addition, increased CSF MMP-3 and MMP-9 levels in healthy elderly individuals correlated with the CSF levels of T-tau and P-tau.</s><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In contrast, no correlations were seen with CSF levels of Aβ42, which is surprising due to the possible relation between MMP-9 and amyloid pathology seen in animal models and the fact that Aβ42 is thought to be the first biomarker to be changed in preclinical AD [<xref rid='B36' ref-type='bibr'>36</xref>].</s><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, a recent neuropathologic study reports that elevated MMP-9 activity correlates with Braak stage but not with NIA-Reagan diagnosis [<xref rid='B37' ref-type='bibr'>37</xref>].</s><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The major difference between Braak stage and the NIA-Reagan criteria is that the former only evaluates presence of tau pathology, whereas the latter evaluates presence of both tau and amyloid pathology [<xref rid='B38' ref-type='bibr'>38</xref>,<xref rid='B39' ref-type='bibr'>39</xref>].</s><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> In summary, our findings suggest that MMPs may be associated with AD pathology as well as with the presence of neuronal degeneration and formation of neurofibrillary tangles already in cognitively unaffected individuals.</s></p><p><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Healthy elderly individuals with at least one <italic>APOE </italic>ε4 allele exhibit a three-fold increased risk of developing AD later on and are thereby more likely to have ongoing progressive neurodegenerative processes in the brain [<xref rid='B1' ref-type='bibr'>1</xref>].</s><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> The higher CSF MMP-3 and MMP-9 levels seen in the healthy elderly individuals with at least one <italic>APOE </italic>ε4 allele in the present study, further supports a probable relation between MMPs and the presence of preclinical AD pathology.</s><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In alignment with this finding, Saarela and colleagues [<xref rid='B40' ref-type='bibr'>40</xref>] have previously shown that the presence of the <italic>APOE </italic>ε4 allele together with a certain MMP-3 polymorphism increases the risk for developing AD in cognitively unaffected elderly individuals more than the presence of <italic>APOE </italic>ε4 allele alone [<xref rid='B40' ref-type='bibr'>40</xref>].</s></p><p><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>A limitation of the study might be that CSF T-tau, P-tau and Aβ42 levels were measured with different methods in the AD patients compared with the healthy elderly individuals.</s><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The aim of the present study, however, was not to make group comparisons of these three CSF biomarkers.</s><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Instead, they were used to employ correlations with other markers within each group and to define 'individuals within the control group with increased risk for future AD'.</s><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The group difference in the CSF analysis method should therefore not influence the findings of the study.</s><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Moreover, it should be stated that the present data do not suggest MMP and TIMP-1 levels to be used for diagnostic discrimination.</s><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> For this purpose, the overlap between the groups are too great and the discriminatory ability too low compared with currently accepted biomarkers such as CSF T-tau, P-tau and Aβ42.</s><s sid='127'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Similarly, the specificity of MMP and TIMP-1 levels to AD can not be evaluated in the present study because it was not designed to study other dementia disorders than AD.</s><s sid='128'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Another limitation could be that extensive neuropsychological testing was not performed on the control individuals and that cognitive follow-up currently only exists up to the time of inclusion.</s><s sid='129'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> However, the cognitive assessments performed at and prior to the inclusion together with the extensive clinical assessment should have minimized the presence of early-stage cognitive impairment in the control group.</s><s sid='130'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Despite these efforts complete absence of preclinical cognitive impairment in the group can not be ensured.</s></p></sec><sec><title>Conclusions</title><p><s sid='131'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>In the present study, the CSF MMP-9/TIMP-1 ratio was increased in AD patients, and correlated with the neuronal degeneration marker tau.</s><s sid='132'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> More importantly, cognitively healthy elderly individuals, with increased risk of developing AD in the future, had elevated CSF MMP-3 and MMP-9 levels and an increased CSF MMP-3/TIMP-1 ratio, indicating that MMP-3 and MMP-9 might be involved in early pathogenesis of AD.</s><s sid='133'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Moreover, CSF levels of MMP-3 and MMP-9 correlated with both CSF T-tau and P-tau in elderly controls, suggesting that MMPs could be associated with neuronal degeneration and/or the formation of P-tau-containing neurofibrillary tangles in individuals who have not yet developed any overt cognitive dysfunction.</s></p></sec><sec><title>Abbreviations</title><p>Aβ: β-amyloid; AD: Alzheimer's disease; ADAS-cog: Alzheimer's Disease Assessment Scale; APOE: apolipoprotein E; AQT: A Quick Test of cognitive speed; CSF: cerebrospinal fluid; ELISA: enzyme-linked immunosorbent assay; MCI: mild cognitive impairment; MMP: matrix metalloproteinase; MT-MMP: membrane-type MMP; P-tau: phosphorylated tau; MMSE: mini mental state examination; TIMP: tissue inhibitor of metalloproteinase; T-tau: total tau.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>ES participated in the design of the study, acquisition of data, statistical analysis and drafted the manuscript. MB performed the immunoassays. SJ performed the immunoassays. LM conceived the study. OH conceived the study, participated in the design of the study, performed the statistical analysis and drafted the manuscript All authors read and approved the final manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>We would like to thank laboratory assistant Marit Emilsson for assistance in the TIMP-1 analysis. This study was supported by unconditional grants by the Swedish Research Council; Stiftelsen för Gamla Tjänarinnor; Skåne county council's research and development foundation; The Swedish Society of Medicine; The Swedish Brain Power; The Trolle-Wachtmeister foundation and The regional agreement on medical training and clinical research (ALF) between Skåne County Council and Lund University.</p></sec><ref-list><ref id='B1'><mixed-citation publication-type='journal'><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>de Leon</surname><given-names>MJ</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><article-title>Alzheimer's disease</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>387</fpage><lpage>403</lpage><pub-id pub-id-type='doi'>10.1016/S0140-6736(06)69113-7</pub-id><pub-id pub-id-type='pmid'>16876668</pub-id></mixed-citation></ref><ref id='B2'><mixed-citation publication-type='journal'><name><surname>Rosenberg</surname><given-names>GA</given-names></name><article-title>Matrix metalloproteinases and their multiple roles in neurodegenerative diseases</article-title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type='doi'>10.1016/S1474-4422(09)70016-X</pub-id><pub-id pub-id-type='pmid'>19161911</pub-id></mixed-citation></ref><ref id='B3'><mixed-citation publication-type='journal'><name><surname>Yong</surname><given-names>VW</given-names></name><name><surname>Power</surname><given-names>C</given-names></name><name><surname>Forsyth</surname><given-names>P</given-names></name><name><surname>Edwards</surname><given-names>DR</given-names></name><article-title>Metalloproteinases in biology and pathology of the nervous system</article-title><source>Nat Rev Neurosci</source><year>2001</year><volume>2</volume><fpage>502</fpage><lpage>511</lpage><pub-id pub-id-type='doi'>10.1038/35081571</pub-id><pub-id pub-id-type='pmid'>11433375</pub-id></mixed-citation></ref><ref id='B4'><mixed-citation publication-type='journal'><name><surname>Miners</surname><given-names>JS</given-names></name><name><surname>Baig</surname><given-names>S</given-names></name><name><surname>Palmer</surname><given-names>J</given-names></name><name><surname>Palmer</surname><given-names>LE</given-names></name><name><surname>Kehoe</surname><given-names>PG</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><article-title>Abeta-degrading enzymes in Alzheimer's disease</article-title><source>Brain Pathol</source><year>2008</year><volume>18</volume><fpage>240</fpage><lpage>252</lpage><pub-id pub-id-type='doi'>10.1111/j.1750-3639.2008.00132.x</pub-id><pub-id pub-id-type='pmid'>18363935</pub-id></mixed-citation></ref><ref id='B5'><mixed-citation publication-type='journal'><name><surname>Gardner</surname><given-names>J</given-names></name><name><surname>Ghorpade</surname><given-names>A</given-names></name><article-title>Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system</article-title><source>J Neurosci Res</source><year>2003</year><volume>74</volume><fpage>801</fpage><lpage>806</lpage><pub-id pub-id-type='doi'>10.1002/jnr.10835</pub-id><pub-id pub-id-type='pmid'>14648584</pub-id></mixed-citation></ref><ref id='B6'><mixed-citation publication-type='journal'><name><surname>Asahina</surname><given-names>M</given-names></name><name><surname>Yoshiyama</surname><given-names>Y</given-names></name><name><surname>Hattori</surname><given-names>T</given-names></name><article-title>Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain</article-title><source>Clin Neuropathol</source><year>2001</year><volume>20</volume><fpage>60</fpage><lpage>63</lpage><pub-id pub-id-type='pmid'>11327298</pub-id></mixed-citation></ref><ref id='B7'><mixed-citation publication-type='journal'><name><surname>Yoshiyama</surname><given-names>Y</given-names></name><name><surname>Asahina</surname><given-names>M</given-names></name><name><surname>Hattori</surname><given-names>T</given-names></name><article-title>Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain</article-title><source>Acta Neuropathol</source><year>2000</year><volume>99</volume><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type='doi'>10.1007/PL00007428</pub-id><pub-id pub-id-type='pmid'>10672313</pub-id></mixed-citation></ref><ref id='B8'><mixed-citation publication-type='journal'><name><surname>Backstrom</surname><given-names>JR</given-names></name><name><surname>Lim</surname><given-names>GP</given-names></name><name><surname>Cullen</surname><given-names>MJ</given-names></name><name><surname>Tokes</surname><given-names>ZA</given-names></name><article-title>Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40)</article-title><source>J Neurosci</source><year>1996</year><volume>16</volume><fpage>7910</fpage><lpage>7919</lpage><pub-id pub-id-type='pmid'>8987819</pub-id></mixed-citation></ref><ref id='B9'><mixed-citation publication-type='journal'><name><surname>Deb</surname><given-names>S</given-names></name><name><surname>Gottschall</surname><given-names>PE</given-names></name><article-title>Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides</article-title><source>J Neurochem</source><year>1996</year><volume>66</volume><fpage>1641</fpage><lpage>1647</lpage><pub-id pub-id-type='pmid'>8627321</pub-id></mixed-citation></ref><ref id='B10'><mixed-citation publication-type='journal'><name><surname>Mizoguchi</surname><given-names>H</given-names></name><name><surname>Takuma</surname><given-names>K</given-names></name><name><surname>Fukuzaki</surname><given-names>E</given-names></name><name><surname>Ibi</surname><given-names>D</given-names></name><name><surname>Someya</surname><given-names>E</given-names></name><name><surname>Akazawa</surname><given-names>KH</given-names></name><name><surname>Alkam</surname><given-names>T</given-names></name><name><surname>Tsunekawa</surname><given-names>H</given-names></name><name><surname>Mouri</surname><given-names>A</given-names></name><name><surname>Noda</surname><given-names>Y</given-names></name><name><surname>Nabeshima</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><article-title>Matrix metalloprotease-9 inhibition improves amyloid beta-mediated cognitive impairment and neurotoxicity in mice</article-title><source>J Pharmacol Exp Ther</source><year>2009</year><volume>331</volume><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type='doi'>10.1124/jpet.109.154724</pub-id><pub-id pub-id-type='pmid'>19587312</pub-id></mixed-citation></ref><ref id='B11'><mixed-citation publication-type='journal'><name><surname>Reitz</surname><given-names>C</given-names></name><name><surname>van Rooij</surname><given-names>FJ</given-names></name><name><surname>Soares</surname><given-names>HD</given-names></name><name><surname>de Maat</surname><given-names>MP</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Witteman</surname><given-names>JC</given-names></name><name><surname>Breteler</surname><given-names>MM</given-names></name><article-title>Matrix metalloproteinase 3 haplotypes and plasma amyloid beta levels: The Rotterdam Study</article-title><source>Neurobiol Aging</source><year>2010</year><volume>31</volume><fpage>715</fpage><lpage>718</lpage><pub-id pub-id-type='doi'>10.1016/j.neurobiolaging.2008.05.033</pub-id><pub-id pub-id-type='pmid'>18606478</pub-id></mixed-citation></ref><ref id='B12'><mixed-citation publication-type='journal'><name><surname>Talamagas</surname><given-names>AA</given-names></name><name><surname>Efthimiopoulos</surname><given-names>S</given-names></name><name><surname>Tsilibary</surname><given-names>EC</given-names></name><name><surname>Figueiredo-Pereira</surname><given-names>ME</given-names></name><name><surname>Tzinia</surname><given-names>AK</given-names></name><article-title>Abeta(1-40)-induced secretion of matrix metalloproteinase-9 results in sAPPalpha release by association with cell surface APP</article-title><source>Neurobiol Dis</source><year>2007</year><volume>28</volume><fpage>304</fpage><lpage>315</lpage><pub-id pub-id-type='doi'>10.1016/j.nbd.2007.07.016</pub-id><pub-id pub-id-type='pmid'>17761425</pub-id></mixed-citation></ref><ref id='B13'><mixed-citation publication-type='journal'><name><surname>Yan</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Yin</surname><given-names>K</given-names></name><name><surname>Bateman</surname><given-names>RJ</given-names></name><name><surname>Cirrito</surname><given-names>JR</given-names></name><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Hsu</surname><given-names>FF</given-names></name><name><surname>Turk</surname><given-names>JW</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><article-title>Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>24566</fpage><lpage>24574</lpage><pub-id pub-id-type='doi'>10.1074/jbc.M602440200</pub-id><pub-id pub-id-type='pmid'>16787929</pub-id></mixed-citation></ref><ref id='B14'><mixed-citation publication-type='journal'><name><surname>Blennow</surname><given-names>K</given-names></name><article-title>CSF biomarkers for mild cognitive impairment</article-title><source>J Intern Med</source><year>2004</year><volume>256</volume><fpage>224</fpage><lpage>234</lpage><pub-id pub-id-type='doi'>10.1111/j.1365-2796.2004.01368.x</pub-id><pub-id pub-id-type='pmid'>15324365</pub-id></mixed-citation></ref><ref id='B15'><mixed-citation publication-type='journal'><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Buchhave</surname><given-names>P</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><article-title>Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study</article-title><source>Lancet Neurol</source><year>2006</year><volume>5</volume><fpage>228</fpage><lpage>234</lpage><pub-id pub-id-type='doi'>10.1016/S1474-4422(06)70355-6</pub-id><pub-id pub-id-type='pmid'>16488378</pub-id></mixed-citation></ref><ref id='B16'><mixed-citation publication-type='journal'><name><surname>Mattsson</surname><given-names>N</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Parnetti</surname><given-names>L</given-names></name><name><surname>Jonsson</surname><given-names>M</given-names></name><name><surname>Herukka</surname><given-names>SK</given-names></name><name><surname>van der Flier</surname><given-names>WM</given-names></name><name><surname>Blankenstein</surname><given-names>MA</given-names></name><name><surname>Ewers</surname><given-names>M</given-names></name><name><surname>Rich</surname><given-names>K</given-names></name><name><surname>Kaiser</surname><given-names>E</given-names></name><name><surname>Verbeek</surname><given-names>M</given-names></name><name><surname>Tsolaki</surname><given-names>M</given-names></name><name><surname>Mulugeta</surname><given-names>E</given-names></name><name><surname>Rosén</surname><given-names>E</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Visser</surname><given-names>PJ</given-names></name><name><surname>Schröder</surname><given-names>J</given-names></name><name><surname>Marcusson</surname><given-names>J</given-names></name><name><surname>de Leon</surname><given-names>M</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Pirttilä</surname><given-names>T</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Jönhagen</surname><given-names>ME</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><article-title>CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>385</fpage><lpage>393</lpage><pub-id pub-id-type='doi'>10.1001/jama.2009.1064</pub-id><pub-id pub-id-type='pmid'>19622817</pub-id></mixed-citation></ref><ref id='B17'><mixed-citation publication-type='journal'><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Vanderstichele</surname><given-names>H</given-names></name><name><surname>Knapik-Czajka</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Soares</surname><given-names>H</given-names></name><name><surname>Simon</surname><given-names>A</given-names></name><name><surname>Lewczuk</surname><given-names>P</given-names></name><name><surname>Dean</surname><given-names>R</given-names></name><name><surname>Siemers</surname><given-names>E</given-names></name><name><surname>Potter</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><collab>Alzheimer's Disease Neuroimaging Initiative</collab><article-title>Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects</article-title><source>Ann Neurol</source><year>2009</year><volume>65</volume><fpage>403</fpage><lpage>413</lpage><pub-id pub-id-type='doi'>10.1002/ana.21610</pub-id><pub-id pub-id-type='pmid'>19296504</pub-id></mixed-citation></ref><ref id='B18'><mixed-citation publication-type='journal'><name><surname>Fagan</surname><given-names>AM</given-names></name><name><surname>Roe</surname><given-names>CM</given-names></name><name><surname>Xiong</surname><given-names>C</given-names></name><name><surname>Mintun</surname><given-names>MA</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><article-title>Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults</article-title><source>Arch Neurol</source><year>2007</year><volume>64</volume><fpage>343</fpage><lpage>349</lpage><pub-id pub-id-type='doi'>10.1001/archneur.64.3.noc60123</pub-id><pub-id pub-id-type='pmid'>17210801</pub-id></mixed-citation></ref><ref id='B19'><mixed-citation publication-type='journal'><name><surname>Gustafson</surname><given-names>DR</given-names></name><name><surname>Skoog</surname><given-names>I</given-names></name><name><surname>Rosengren</surname><given-names>L</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><article-title>Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2007</year><volume>78</volume><fpage>461</fpage><lpage>464</lpage><pub-id pub-id-type='doi'>10.1136/jnnp.2006.100529</pub-id><pub-id pub-id-type='pmid'>17098843</pub-id></mixed-citation></ref><ref id='B20'><mixed-citation publication-type='journal'><name><surname>Stomrud</surname><given-names>E</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><article-title>Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly</article-title><source>Dement Geriatr Cogn Disord</source><year>2007</year><volume>24</volume><fpage>118</fpage><lpage>124</lpage><pub-id pub-id-type='doi'>10.1159/000105017</pub-id><pub-id pub-id-type='pmid'>17622715</pub-id></mixed-citation></ref><ref id='B21'><mixed-citation publication-type='book'><collab>American Psychiatric Association</collab><source>Diagnostic and Statistical Manual of Mental Disorders, revised (DSM-IIIR)</source><year>1987</year><edition>3</edition><publisher-name>Arlington, VA, USA: American Psychiatric Association</publisher-name></mixed-citation></ref><ref id='B22'><mixed-citation publication-type='journal'><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name><article-title>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type='pmid'>6610841</pub-id></mixed-citation></ref><ref id='B23'><mixed-citation publication-type='journal'><name><surname>Petersen</surname><given-names>RC</given-names></name><article-title>Mild cognitive impairment as a diagnostic entity</article-title><source>J Intern Med</source><year>2004</year><volume>256</volume><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type='doi'>10.1111/j.1365-2796.2004.01388.x</pub-id><pub-id pub-id-type='pmid'>15324362</pub-id></mixed-citation></ref><ref id='B24'><mixed-citation publication-type='journal'><name><surname>Crum</surname><given-names>RM</given-names></name><name><surname>Anthony</surname><given-names>JC</given-names></name><name><surname>Bassett</surname><given-names>SS</given-names></name><name><surname>Folstein</surname><given-names>MF</given-names></name><article-title>Population-based norms for the Mini-Mental State Examination by age and educational level</article-title><source>JAMA</source><year>1993</year><volume>269</volume><fpage>2386</fpage><lpage>2391</lpage><pub-id pub-id-type='doi'>10.1001/jama.269.18.2386</pub-id><pub-id pub-id-type='pmid'>8479064</pub-id></mixed-citation></ref><ref id='B25'><mixed-citation publication-type='journal'><name><surname>Bravo</surname><given-names>G</given-names></name><name><surname>Hebert</surname><given-names>R</given-names></name><article-title>Age- and education-specific reference values for the Mini-Mental and modified Mini-Mental State Examinations derived from a non-demented elderly population</article-title><source>Int J Geriatr Psychiatry</source><year>1997</year><volume>12</volume><fpage>1008</fpage><lpage>1018</lpage><pub-id pub-id-type='doi'>10.1002/(SICI)1099-1166(199710)12:10&lt;1008::AID-GPS676&gt;3.0.CO;2-A</pub-id><pub-id pub-id-type='pmid'>9395933</pub-id></mixed-citation></ref><ref id='B26'><mixed-citation publication-type='journal'><name><surname>Huppert</surname><given-names>FA</given-names></name><name><surname>Cabelli</surname><given-names>ST</given-names></name><name><surname>Matthews</surname><given-names>FE</given-names></name><article-title>Brief cognitive assessment in a UK population sample -- distributional properties and the relationship between the MMSE and an extended mental state examination</article-title><source>BMC Geriatr</source><year>2005</year><volume>5</volume><fpage>7</fpage><pub-id pub-id-type='doi'>10.1186/1471-2318-5-7</pub-id><pub-id pub-id-type='pmid'>15869717</pub-id></mixed-citation></ref><ref id='B27'><mixed-citation publication-type='journal'><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Agren</surname><given-names>H</given-names></name><name><surname>Spenger</surname><given-names>C</given-names></name><name><surname>Siegfried</surname><given-names>J</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><article-title>Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?</article-title><source>Mol Chem Neuropathol</source><year>1995</year><volume>26</volume><fpage>231</fpage><lpage>245</lpage><pub-id pub-id-type='doi'>10.1007/BF02815140</pub-id><pub-id pub-id-type='pmid'>8748926</pub-id></mixed-citation></ref><ref id='B28'><mixed-citation publication-type='journal'><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Hesse</surname><given-names>C</given-names></name><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Vanderstichele</surname><given-names>H</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><article-title>Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease</article-title><source>Arch Neurol</source><year>1999</year><volume>56</volume><fpage>673</fpage><lpage>680</lpage><pub-id pub-id-type='doi'>10.1001/archneur.56.6.673</pub-id><pub-id pub-id-type='pmid'>10369305</pub-id></mixed-citation></ref><ref id='B29'><mixed-citation publication-type='journal'><name><surname>Olsson</surname><given-names>A</given-names></name><name><surname>Vanderstichele</surname><given-names>H</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>De Meyer</surname><given-names>G</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Holmberg</surname><given-names>B</given-names></name><name><surname>Rosengren</surname><given-names>L</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><article-title>Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology</article-title><source>Clin Chem</source><year>2005</year><volume>51</volume><fpage>336</fpage><lpage>345</lpage><pub-id pub-id-type='doi'>10.1373/clinchem.2004.039347</pub-id><pub-id pub-id-type='pmid'>15563479</pub-id></mixed-citation></ref><ref id='B30'><mixed-citation publication-type='journal'><name><surname>Lorenzl</surname><given-names>S</given-names></name><name><surname>Buerger</surname><given-names>K</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Beal</surname><given-names>MF</given-names></name><article-title>Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia</article-title><source>Int Psychogeriatr</source><year>2008</year><volume>20</volume><fpage>67</fpage><lpage>76</lpage><pub-id pub-id-type='doi'>10.1017/S1041610207005790</pub-id><pub-id pub-id-type='pmid'>17697439</pub-id></mixed-citation></ref><ref id='B31'><mixed-citation publication-type='journal'><name><surname>Lorenzl</surname><given-names>S</given-names></name><name><surname>Albers</surname><given-names>DS</given-names></name><name><surname>Relkin</surname><given-names>N</given-names></name><name><surname>Ngyuen</surname><given-names>T</given-names></name><name><surname>Hilgenberg</surname><given-names>SL</given-names></name><name><surname>Chirichigno</surname><given-names>J</given-names></name><name><surname>Cudkowicz</surname><given-names>ME</given-names></name><name><surname>Beal</surname><given-names>MF</given-names></name><article-title>Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease</article-title><source>Neurochem Int</source><year>2003</year><volume>43</volume><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type='doi'>10.1016/S0197-0186(03)00004-4</pub-id><pub-id pub-id-type='pmid'>12689599</pub-id></mixed-citation></ref><ref id='B32'><mixed-citation publication-type='journal'><name><surname>Helbecque</surname><given-names>N</given-names></name><name><surname>Cottel</surname><given-names>D</given-names></name><name><surname>Hermant</surname><given-names>X</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name><article-title>Impact of the matrix metalloproteinase MMP-3 on dementia</article-title><source>Neurobiol Aging</source><year>2007</year><volume>28</volume><fpage>1215</fpage><lpage>1220</lpage><pub-id pub-id-type='doi'>10.1016/j.neurobiolaging.2006.05.030</pub-id><pub-id pub-id-type='pmid'>16822591</pub-id></mixed-citation></ref><ref id='B33'><mixed-citation publication-type='journal'><name><surname>Jourquin</surname><given-names>J</given-names></name><name><surname>Tremblay</surname><given-names>E</given-names></name><name><surname>Decanis</surname><given-names>N</given-names></name><name><surname>Charton</surname><given-names>G</given-names></name><name><surname>Hanessian</surname><given-names>S</given-names></name><name><surname>Chollet</surname><given-names>AM</given-names></name><name><surname>Le Diguardher</surname><given-names>T</given-names></name><name><surname>Khrestchatisky</surname><given-names>M</given-names></name><name><surname>Rivera</surname><given-names>S</given-names></name><article-title>Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate</article-title><source>Eur J Neurosci</source><year>2003</year><volume>18</volume><fpage>1507</fpage><lpage>1517</lpage><pub-id pub-id-type='doi'>10.1046/j.1460-9568.2003.02876.x</pub-id><pub-id pub-id-type='pmid'>14511330</pub-id></mixed-citation></ref><ref id='B34'><mixed-citation publication-type='journal'><name><surname>Skoog</surname><given-names>I</given-names></name><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Aevarsson</surname><given-names>O</given-names></name><name><surname>Vanderstichele</surname><given-names>H</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><article-title>Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds</article-title><source>Dement Geriatr Cogn Disord</source><year>2003</year><volume>15</volume><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type='doi'>10.1159/000068478</pub-id><pub-id pub-id-type='pmid'>12584433</pub-id></mixed-citation></ref><ref id='B35'><mixed-citation publication-type='journal'><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Sokal</surname><given-names>I</given-names></name><name><surname>Quinn</surname><given-names>JF</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Brodey</surname><given-names>M</given-names></name><name><surname>Schellenberg</surname><given-names>GD</given-names></name><name><surname>Kaye</surname><given-names>JA</given-names></name><name><surname>Raskind</surname><given-names>MA</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><article-title>CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study</article-title><source>Neurology</source><year>2007</year><volume>69</volume><fpage>631</fpage><lpage>639</lpage><pub-id pub-id-type='doi'>10.1212/01.wnl.0000267428.62582.aa</pub-id><pub-id pub-id-type='pmid'>17698783</pub-id></mixed-citation></ref><ref id='B36'><mixed-citation publication-type='journal'><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Weiner</surname><given-names>MW</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><article-title>Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade</article-title><source>Lancet Neurol</source><year>2010</year><volume>9</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type='doi'>10.1016/S1474-4422(09)70299-6</pub-id><pub-id pub-id-type='pmid'>20083042</pub-id></mixed-citation></ref><ref id='B37'><mixed-citation publication-type='journal'><name><surname>Bruno</surname><given-names>MA</given-names></name><name><surname>Mufson</surname><given-names>EJ</given-names></name><name><surname>Wuu</surname><given-names>J</given-names></name><name><surname>Cuello</surname><given-names>AC</given-names></name><article-title>Increased matrix metalloproteinase 9 activity in mild cognitive impairment</article-title><source>J Neuropathol Exp Neurol</source><year>2009</year><volume>68</volume><fpage>1309</fpage><lpage>1318</lpage><pub-id pub-id-type='doi'>10.1097/NEN.0b013e3181c22569</pub-id><pub-id pub-id-type='pmid'>19915485</pub-id></mixed-citation></ref><ref id='B38'><mixed-citation publication-type='journal'><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol</source><year>1991</year><volume>82</volume><fpage>239</fpage><lpage>259</lpage><pub-id pub-id-type='doi'>10.1007/BF00308809</pub-id><pub-id pub-id-type='pmid'>1759558</pub-id></mixed-citation></ref><ref id='B39'><mixed-citation publication-type='journal'><collab>The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease</collab><article-title>Consensus recommendations for the postmortem diagnosis of Alzheimer's disease</article-title><source>Neurobiol Aging</source><year>1997</year><volume>18</volume><fpage>S1</fpage><lpage>2</lpage><pub-id pub-id-type='doi'>10.1016/S0197-4580(97)00057-2</pub-id><pub-id pub-id-type='pmid'>9330978</pub-id></mixed-citation></ref><ref id='B40'><mixed-citation publication-type='journal'><name><surname>Saarela</surname><given-names>MS</given-names></name><name><surname>Lehtimaki</surname><given-names>T</given-names></name><name><surname>Rinne</surname><given-names>JO</given-names></name><name><surname>Hervonen</surname><given-names>A</given-names></name><name><surname>Jylha</surname><given-names>M</given-names></name><name><surname>Roytta</surname><given-names>M</given-names></name><name><surname>Ahonen</surname><given-names>JP</given-names></name><name><surname>Mattila</surname><given-names>KM</given-names></name><article-title>Interaction between matrix metalloproteinase 3 and the epsilon4 allele of apolipoprotein E increases the risk of Alzheimer's disease in Finns</article-title><source>Neurosci Lett</source><year>2004</year><volume>367</volume><fpage>336</fpage><lpage>339</lpage><pub-id pub-id-type='doi'>10.1016/j.neulet.2004.06.027</pub-id><pub-id pub-id-type='pmid'>15337261</pub-id></mixed-citation></ref></ref-list></back></article></PAPER>